Cargando…
Benefits of Using Dapsone in Patients Hospitalized with COVID-19
Since the start of the SARS-CoV-2 pandemic, refractory and relentless hypoxia as a consequence of exuberant lung inflammation and parenchymal damage remains the main cause of death. We have earlier reported results of the addition of dapsone in this population to the standard of care. We now report...
Autores principales: | Kanwar, Badar A., Khattak, Asif, Balentine, Jenny, Lee, Jong Hoon, Kast, Richard E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879930/ https://www.ncbi.nlm.nih.gov/pubmed/35214654 http://dx.doi.org/10.3390/vaccines10020195 |
Ejemplares similares
-
Dapsone Lowers Neutrophil to Lymphocyte Ratio and Mortality in COVID-19 Patients Admitted to the ICU
por: Kanwar, Badar, et al.
Publicado: (2022) -
Dapsone is an anticatalysis for Alzheimer’s disease exacerbation
por: Lee, Jong Hoon, et al.
Publicado: (2022) -
COVID-19 Molecular Pathophysiology: Acetylation of Repurposing Drugs
por: Lee, Jong Hoon, et al.
Publicado: (2022) -
Commentary for the Elderly in the Pandemic Era
por: Khattak, Asif, et al.
Publicado: (2021) -
Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness
por: Kast, R. E.
Publicado: (2015)